Finanzen von Parabilis Medicines Inc (PBLS)PBLSParabilis Medicines Inc

Evaluating the bottom line, Parabilis Medicines Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -66445.27%, while the net margin is -66066.89%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PBLS converts its operational activities into shareholder value.

In the context of the broader market, PBLS competes directly with industry leaders such as LQDA and VCRE. With a market capitalization of $3.13B, it holds a leading position in the sector. When comparing efficiency, PBLS's gross margin of 100.00% stands against LQDA's 93.27% and VCRE's N/A. Such benchmarking helps identify whether Parabilis Medicines Inc is trading at a premium or discount relative to its financial performance.

The company reported total revenue of $148,000 in Q2 2026, with a gross margin of 100% for that quarter, but it has consistently posted significant net income losses, including -$66,955,000 in Q2 2026. The forward P/E ratio is 0, indicating no earnings growth expected in the near term.